{"id":"arv-bitherapie","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Lipid abnormalities"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This dual-therapy approach combines two antiretroviral agents to inhibit different steps of the HIV replication cycle, reducing viral load and slowing disease progression. The specific agents in this ANRS-developed regimen are selected to provide efficacy while potentially reducing pill burden and adverse event profiles compared to standard triple-therapy regimens.","oneSentence":"ARV bitherapie is a two-drug antiretroviral combination regimen designed to suppress HIV replication by targeting viral reverse transcriptase and/or protease enzymes.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:02:39.059Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (investigational two-drug regimen)"}]},"trialDetails":[{"nctId":"NCT04867083","phase":"PHASE3","title":"Dual Therapy in HIV Patients in 4 Days a Week Versus 7 Days a Week","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-06-21","conditions":"HIV Infections","enrollment":440}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ARV bitherapie","genericName":"ARV bitherapie","companyName":"ANRS, Emerging Infectious Diseases","companyId":"anrs-emerging-infectious-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ARV bitherapie is a two-drug antiretroviral combination regimen designed to suppress HIV replication by targeting viral reverse transcriptase and/or protease enzymes. Used for HIV-1 infection (investigational two-drug regimen).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}